Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KYAT1 | Q16773 | 6/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836647 | 1.00 | APOBEC3A (0.37) | APOBEC3AAPOBEC3GALDH1A1FAAHMAPT | |
| SCHEMBL9526390 | 0.86 | APOBEC3A (0.36) | APOBEC3AAPOBEC3GALDH1A1FAAHMAPT | |
| SCHEMBL9526395 | 0.86 | APOBEC3A (0.36) | APOBEC3AAPOBEC3GALDH1A1FAAHMAPT | |
| SCHEMBL29134126 | 0.83 | MAPT (0.38) | APOBEC3AAPOBEC3GALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20778292 | 0.83 | MAPT (0.38) | APOBEC3AAPOBEC3GALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9754039 | 0.81 | HAO1 (0.46) | ALDH1A1MAPTHAO1CES2CES1 | |
| SCHEMBL9057737 | 0.81 | HAO1 (0.46) | ALDH1A1MAPTHAO1CES2CES1 | |
| SCHEMBL950647 | 0.78 | MAPT (0.43) | APOBEC3AAPOBEC3GALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14487036 | 0.78 | MAPT (0.43) | APOBEC3AAPOBEC3GALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL950646 | 0.78 | MAPT (0.43) | APOBEC3AAPOBEC3GALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | BANTAM PHARMACEUTICAL, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20200261424-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | BANTAM PHARMACEUTICAL, LLC | 2020-08-20 | — | — | US | disclosed |
| US-20200069656-A1 | Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2020-03-05 | — | — | US | disclosed |
| CN-110769823-A | Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3548024-A2 | METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bantam Pharmaceutical, LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180311218-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | EGENIX, INC. | 2018-11-01 | — | — | US | disclosed |
| WO-2018102452-A2 | METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | BANTAM PHARMACEUTICAL, LLC (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-3303332-A1 | SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO | Bantam Pharmaceutical, LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196644-A1 | SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO | BANTAM PHARMACEUTICAL, LLC (US) | 2016-12-08 | — | — | WO | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5789415-A | Azacyclic-heterocyclic compounds as angiotension II receptor antagonists | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5496835-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0603712-A2 | Heterocyclic compounds having angiotensin II antagonistic activity and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-29 | — | — | EP | disclosed |
| US-5262412-A | Angiotensin II antagonists, hypotensive agents, treatment of congestive heart failure and glaucoma | MERCK & CO., INC. (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0523141-A4 | SUBSTITUTED PYRAZOLES, ISOXAZOLES AND ISOTHIAZOLES | — | 1993-04-21 | — | — | EP | disclosed |
| EP-0523141-A1 | SUBSTITUTED PYRAZOLES, ISOXAZOLES AND ISOTHIAZOLES | MERCK & CO. INC. (US) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991015479-A1 | SUBSTITUTED PYRAZOLES, ISOXAZOLES AND ISOTHIAZOLES | MERCK & CO., INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261424-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | EIF4A1, EIF4A3, EIF4B | APOBEC3A 2517/4885APOBEC3G 2320/4885ALDH1A1 3399/4885 |
| US-20180311218-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | EIF4A3, EIF4A1, EIF4B | APOBEC3A 2152/4885APOBEC3G 1928/4885ALDH1A1 2335/4885 |
| US-20200069656-A1 | Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases | KRAS, TP53, CCNA1 | APOBEC3A 2333/4885APOBEC3G 2759/4885ALDH1A1 480/4885 |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | KRAS, TP53, CCNA1 | APOBEC3A 2333/4885APOBEC3G 2759/4885ALDH1A1 480/4885 |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | EIF4A1, EIF4A3, EIF4B | APOBEC3A 2517/4885APOBEC3G 2320/4885ALDH1A1 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.